PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.47%
Revenue growth at 75-90% of MCHP's 8.54%. Bill Ackman would push for innovation or market expansion to catch up.
13.31%
Gross profit growth above 1.5x MCHP's 3.21%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
37.52%
EBIT growth 50-75% of MCHP's 61.29%. Martin Whitman would suspect suboptimal resource allocation.
-6.84%
Negative operating income growth while MCHP is at 115.13%. Joel Greenblatt would press for urgent turnaround measures.
-4.70%
Negative net income growth while MCHP stands at 148.02%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-5.08%
Negative EPS growth while MCHP is at 145.45%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-3.45%
Negative diluted EPS growth while MCHP is at 145.79%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.63%
Share reduction while MCHP is at 1.23%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.54%
Reduced diluted shares while MCHP is at 5.33%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.31%
Maintaining or increasing dividends while MCHP cut them. John Neff might see a strong edge in shareholder returns.
70.77%
OCF growth at 50-75% of MCHP's 103.64%. Martin Whitman would question if the firm lags in monetizing sales effectively.
77.99%
FCF growth 50-75% of MCHP's 151.19%. Martin Whitman would see if structural disadvantages exist in generating free cash.
100.90%
10Y revenue/share CAGR at 50-75% of MCHP's 158.81%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
13.95%
5Y revenue/share CAGR under 50% of MCHP's 74.88%. Michael Burry would suspect a significant competitive gap or product weakness.
-6.30%
Negative 3Y CAGR while MCHP stands at 56.88%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
254.02%
10Y OCF/share CAGR above 1.5x MCHP's 79.11%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
30.17%
5Y OCF/share CAGR above 1.5x MCHP's 3.61%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-5.66%
Negative 3Y OCF/share CAGR while MCHP stands at 20.45%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
120.73%
Positive 10Y CAGR while MCHP is negative. John Neff might see a substantial advantage in bottom-line trajectory.
32.93%
Positive 5Y CAGR while MCHP is negative. John Neff might view this as a strong mid-term relative advantage.
-20.90%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
51.69%
10Y equity/share CAGR at 50-75% of MCHP's 70.83%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
30.26%
Below 50% of MCHP's 75.91%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
19.84%
3Y equity/share CAGR at 75-90% of MCHP's 22.47%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
1205.79%
10Y dividend/share CAGR at 50-75% of MCHP's 1661.84%. Martin Whitman suspects the firm lags in returning cash to shareholders over the decade.
179.73%
5Y dividend/share CAGR above 1.5x MCHP's 9.89%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
132.68%
3Y dividend/share CAGR above 1.5x MCHP's 3.62%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
2.21%
Our AR growth while MCHP is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
0.35%
We show growth while MCHP is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-0.79%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
0.48%
Positive BV/share change while MCHP is negative. John Neff sees a clear edge over a competitor losing equity.
-0.08%
We’re deleveraging while MCHP stands at 1.22%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-5.40%
Our R&D shrinks while MCHP invests at 11.38%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.27%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.